Related Experiment Video
Updated: Jun 25, 2026
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Deciphering molecular specificity in MCL-1/BAK interaction and its implications for designing potent MCL-1 inhibitors
Hudie Wei1, Haolan Wang1, Shuang Xiang2
1Department of Oncology, NHC Key Laboratory of Cancer Proteomics & State Local Joint Engineering Laboratory for Anticancer Drugs, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Abstract:
The intricate interplay among BCL-2 family proteins governs mitochondrial apoptosis, with the anti-apoptotic protein MCL-1 primarily exerting its function by sequestering the pore-forming effector BAK. Understanding the MCL-1/BAK complex is pivotal for the sensitivity of cancer cells to BH3 mimetics, yet the precise molecular mechanism underlying their interaction remains elusive. Herein, we demonstrate that a canonical BH3 peptide from BAK inadequately binds to MCL-1 proteins, whereas an extended BAK-BH3 peptide with five C-terminal residues exhibits a remarkable 65-fold increase in affinity. By elucidating the complex structures of MCL-1 bound to these two BAK-BH3 peptides at 2.08 Å and 1.98 Å resolutions, we uncover their distinct binding specificities. Notably, MCL-1 engages in critical hydrophobic interactions with the extended BAK-BH3 peptide, particularly at an additional p5 sub-pocket, featuring a π-π stacking interaction between MCL-1 Phe319 and BAK Tyr89. Mutations within this p5 sub-pocket substantially disrupt the MCL-1/BAK protein-protein interaction. Furthermore, the p5 sub-pocket of MCL-1 significantly influences the efficacy of MCL-1 inhibitors. Overall, our findings elucidate the molecular specificity underlying MCL-1 binding to BAK and underscore the significance of the p5 hydrophobic sub-pocket in their high-affinity interaction, thus providing novel insights for the development of BH3 mimetics targeting the MCL-1/BAK interaction as potential therapeutics for cancer treatment.
Insights
Researchers discovered how the MCL-1 protein binds to BAK, revealing a specific interaction crucial for cancer cell death. This finding enhances understanding of BH3 mimetics for cancer therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- The BCL-2 protein family regulates mitochondrial apoptosis.
- MCL-1, an anti-apoptotic protein, inhibits cell death by binding to BAK.
- Understanding MCL-1/BAK interaction is key for developing BH3 mimetics in cancer treatment.
Purpose of the Study:
- To elucidate the molecular mechanism of MCL-1 binding to BAK.
- To investigate the structural basis for the affinity of BAK-derived peptides to MCL-1.
- To identify key interactions influencing MCL-1/BAK complex formation and BH3 mimetic efficacy.
Main Methods:
- X-ray crystallography to determine the structures of MCL-1 bound to BAK-BH3 peptides.
- Site-directed mutagenesis to assess the role of specific amino acid residues and sub-pockets.
- Biochemical assays to measure binding affinities and inhibitor efficacy.
Main Results:
- An extended BAK-BH3 peptide shows a 65-fold higher affinity for MCL-1 compared to a canonical BH3 peptide.
- Crystal structures reveal distinct binding modes and critical hydrophobic interactions, including a π-π stacking in the p5 sub-pocket.
- Mutations in the p5 sub-pocket significantly impair MCL-1/BAK interaction and affect MCL-1 inhibitor efficacy.
Conclusions:
- The p5 hydrophobic sub-pocket of MCL-1 is crucial for high-affinity binding to BAK.
- Distinct binding specificities of BAK-BH3 peptides to MCL-1 are elucidated.
- These findings provide insights for designing novel BH3 mimetics targeting the MCL-1/BAK interaction for cancer therapy.
